Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies

被引:63
|
作者
Xuan, Li [1 ]
Huang, Fen [1 ]
Fan, Zhiping [1 ]
Zhou, Hongsheng [1 ]
Zhang, Xian [1 ]
Yu, Guopan [1 ]
Zhang, Yu [1 ]
Liu, Can [1 ]
Sun, Jing [1 ]
Liu, Qifa [1 ]
机构
[1] So Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou 510515, Guangdong, Peoples R China
来源
基金
中国国家自然科学基金; 高等学校博士学科点专项科研基金;
关键词
Epstein-Barr virus; Cytomegalovirus; Conditioning; Hematological malignancies; Allogeneic hematopoietic stem cell transplantation; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; VERSUS-HOST-DISEASE; HIGH-RISK PATIENTS; IMMUNE RECONSTITUTION; REGIMENS; CHEMOTHERAPY; STRATEGIES;
D O I
10.1186/1756-8722-5-46
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Intensified conditioning regimens (increasing the intensity of standard myeloablative conditioning) for hematological malignancies in allogeneic hematopoietic stem cell transplantation (allo-HSCT) could reduce the relapse rate of the underlying disease, but it might simultaneously increase the transplant-related mortality including the mortality of infections. To explore whether intensified conditioning affected Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections, 185 patients undergoing allo-HSCT were enrolled. Methods: A total of 104 cases received standard and 81 intensified conditioning. Cyclosporine A (CsA) withdrawal and/or donor lymphocyte infusion (DLI) were conducted in high-risk patients. The EBV-DNA and CMV-DNA levels of blood were monitored regularly by quantitative real-time polymerase chain reaction (RQ-PCR) and immune reconstitution of recipients were analyzed by flow cytometry. Results: The 3-year cumulative incidence of EBV viremia, EBV-associated diseases and mortality of EBV-associated diseases were 25.3%+/- 4.6%, 10.5%+/- 3.4% and 0.0%+/- 0.0% in the standard group, compared with 45.6%+/- 6.5%, 26.0%+/- 5.3% and 7.3%+/- 3.1% in the intensified group (P=0.002, P=0.002, P=0.008). The 3-year cumulative incidence of CMV viremia and CMV-associated diseases, mortality of CMV-associated diseases and incidence of bacterial and fungal infections were similar between the two groups (P=0.855, P=0.581, P=0.933, P=0.142, P=0.182, respectively). Multivariate analysis showed that intensified conditioning was one of the risk factors for EBV viremia and EBV-associated diseases (P=0.037, P=0.037), but it had no effects on CMV infections. The percentage of CD4(+) T cells and CD4(+)/CD8(+) ratio at 3 months post-transplantation were lower in the intensified group (P=0.032, P=0.022). The 3-year OS and DFS in the standard group were 62.2%+/- 5.8% and 60.6%+/- 5.6%, compared with 51.6%+/- 6.2% and 51.1% +/- 5.9% in the intensified group (P=0.029, P=0.063). Conclusions: Intensified conditioning represents a promising approach for high-risk hematological malignancies, although it affects early immune reconstitution of recipients and increases the incidence and mortality of EBV infections.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation
    Liu, Li
    Zhang, Xuyan
    Feng, Sizhou
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (07) : 1341 - 1349
  • [42] Clonal gammopathies and Epstein-Barr virus reactivation after allogeneic stem cell transplantation
    Di Nardo, P.
    Bellesi, S.
    Sora, F.
    Laurenti, L.
    Innocenti, I.
    Chiusolo, P.
    Cattani, P.
    Tarnani, M.
    De Matteis, S.
    Leone, G.
    Sica, S.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S285 - S286
  • [43] Epstein-Barr virus driven lymphoproliferative disorders post allogeneic stem cell transplantation
    Lavin, M.
    Crowley, B.
    Browne, P. V.
    Flynn, C.
    Hayden, P.
    Vandenberghe, E.
    O'Neill, G.
    Conneally, E.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S143 - S143
  • [44] Monitoring Epstein-Barr virus in adults following allogeneic haematopoietic stem cell transplantation
    Buchholz, S
    Dammann, E
    Flik, J
    Dobbelstein, C
    Stadler, M
    Kamal, H
    Krauter, J
    Eder, M
    Hertenstein, B
    Schulz, T
    Ganser, A
    BONE MARROW TRANSPLANTATION, 2006, 37 : S169 - S170
  • [45] Association between Antiviral Prophylaxis and Cytomegalovirus and Epstein-Barr Virus DNAemia in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplant
    Diop, Ndeye Soukeyna
    Bonong, Pascal Roland Enok
    Buteau, Chantal
    Duval, Michel
    Lacroix, Jacques
    Laporte, Louise
    Tucci, Marisa
    Robitaille, Nancy
    Spinella, Philip C.
    Cuvelier, Geoffrey
    Vercauteren, Suzanne M.
    Lewis, Victor
    Alfieri, Caroline
    Trottier, Helen
    VACCINES, 2021, 9 (06)
  • [46] Significance of Epstein-Barr Virus DNA Quantitation in Donors of Hematopoietic Stem Cell Transplantation
    Jung, Seungwon
    Lim, Jihyang
    Cho, Byung Sik
    Chae, Hyojin
    Kim, Myungshin
    Kim, Yonggoo
    Han, Kyungja
    Lee, Jong Wook
    Min, Woo Sung
    KOREAN JOURNAL OF LABORATORY MEDICINE, 2010, 30 (06): : 554 - 558
  • [47] Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem cell transplantation
    Ahmad, Imran
    Kwan, John
    Meuleman, Nathalie
    Lewalle, Philippe
    Crokaert, Francoise
    Bron, Dominique
    BLOOD, 2007, 110 (11) : 328B - 328B
  • [48] The efficacy and safety of rituximab in treatment of Epstein-Barr virus disease post allogeneic hematopoietic stem-cell transplantation
    许兰平
    China Medical Abstracts(Internal Medicine), 2013, 30 (01) : 58 - 58
  • [49] Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease
    Kawa, K
    Okamura, T
    Yasui, M
    Sato, E
    Inoue, M
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2002, 44 (03) : 251 - 257
  • [50] Cyclosporine area under the curve after allogeneic hematopoietic stem cell transplantation is an indicator of Epstein-Barr virus DNAemia
    Christopeit, Maximilian
    Janssen, Nils
    Weber, Thomas
    Bacher, Ulrike
    Lautenschlaeger, Christine
    Oehme, Albrecht
    Kekule, Alexander S.
    Schmoll, Hans-Joachim
    LEUKEMIA & LYMPHOMA, 2013, 54 (01) : 133 - 137